Clinical trials on Multiple Sclerosis

Understanding Multiple Sclerosis (MS)

Multiple Sclerosis (MS) is a chronic, potentially debilitating disease that affects the central nervous system, which comprises the brain and spinal cord. It is characterized by the immune system mistakenly attacking the protective sheath (myelin) that covers nerve fibers, causing communication problems between your brain and the rest of your body. Eventually, the disease can cause permanent damage or deterioration of the nerves.

Signs and symptoms of MS vary widely and depend on the amount of nerve damage and which nerves are affected. Some people with severe MS may lose the ability to walk independently, while others may experience long periods of remission without any new symptoms. There’s no cure for multiple sclerosis. However, treatments can help speed recovery from attacks, modify the course of the disease, and manage symptoms.

Key Facts About MS

  • Prevalence: MS affects nearly 2.3 million people worldwide. The condition is more common in women than in men and is usually diagnosed between the ages of 20 and 50.
  • Types of MS: There are several types of MS, including Relapsing-Remitting MS (RRMS), Primary-Progressive MS (PPMS), Secondary-Progressive MS (SPMS), and Progressive-Relapsing MS (PRMS), each with different patterns of symptom progression.
  • Treatment: While there is no cure for MS, various treatment options can help manage symptoms and improve quality of life. These include disease-modifying therapies (DMTs), physical therapy, and medications to manage symptoms like muscle spasms, fatigue, and bladder issues.

Understanding MS is crucial for early diagnosis and treatment, which can significantly impact the progression and severity of the disease. With ongoing research and advancements in medical science, there is hope for new treatments and ultimately, a cure for multiple sclerosis.

Prognosis for Multiple Sclerosis: Understanding the Long-Term Outlook

Multiple Sclerosis (MS) is recognized as a chronic autoimmune disorder that affects the central nervous system, leading to a spectrum of neurological symptoms. The long-term prognosis for MS is highly variable and is influenced by several factors, such as the subtype of MS, age at onset, and initial symptoms. While a benign course with minimal disability may be observed in some cases, more aggressive forms of the disease can result in significant physical and cognitive impairments over time in others. The rate of disease progression is also not consistent, with stability over years in some cases, while a gradual worsening of symptoms may be seen in others. Life expectancy in MS may be slightly reduced in comparison to the general population. Nonetheless, with advancements in medical care and support systems, effective symptom management and the maintenance of a good quality of life are achievable for many affected by MS.

Complications in Multiple Sclerosis

Living with Multiple Sclerosis (MS) can lead to various complications that affect daily life. Common issues include:

  • Mobility challenges due to muscle weakness and coordination problems, which can make walking and balance difficult.
  • Fatigue, often resulting in extreme tiredness that can impact work and social activities.
  • Mental functions may also be affected; memory problems or difficulty focusing are potential challenges.
  • Vision issues, such as blurred or double vision, can arise, complicating tasks like reading and driving.
  • Muscle stiffness and spasms can cause discomfort and limit movement.
  • Emotional changes, including mood swings or depression, may occur, impacting personal relationships and overall well-being.
  • Bladder and bowel dysfunction are also possible, leading to frequent trips to the bathroom or incontinence, which can be both inconvenient and embarrassing.

These complications can significantly impact an individual’s health and quality of life.

Treatment Methods for Multiple Sclerosis

In the management of Multiple Sclerosis (MS), a variety of non-clinical trial treatments are often recommended:

  • Dietary adjustments: A diet balanced in fiber and low in saturated fats may contribute to maintaining overall health. The incorporation of fruits, vegetables, and whole grains is advised, while a gluten-free or low-sodium diet may be beneficial for some.
  • Regular physical activity: Exercises tailored to individual abilities can improve strength, mobility, and mood. Activities such as yoga, swimming, or stretching are particularly beneficial for individuals with MS.
  • Pharmacotherapy options: Not in clinical trials, may include the off-label use of medications that address symptoms like muscle spasticity or fatigue. Consulting healthcare providers for personalized medication plans is important.
  • Modern technology: Provides tools like mobility aids, voice-activated devices, and software adaptations for individuals with physical limitations. Cooling vests and other wearable technologies can assist in regulating body temperature during physical activity.

The adoption of these methods can contribute to the management of MS symptoms and the enhancement of quality of life.

  • CT-EU-00053655

    Further study of ocrelizumab’s impact on multiple sclerosis patients

    This is a follow-up study for people who have already taken part in previous Roche trials. The trials were about how safe and effective a drug called Ocrelizumab is for people with Multiple Sclerosis (MS). In this study, the team will give the same people the Ocrelizumab drug. They’ll get the drug through a drip every 24 weeks for two years. Doctors will measure if their MS gets better, stays the same, or worsens using a test called the EDSS. Doctors will check for any signs of the disease getting active again, such as new spots on an MRI scan.

    • Ocrelizumab
  • Exploring safe treatment options for Multiple Sclerosis

    This study is investigating the effects of Ofatumumab and Siponimod in comparison to a medication called Fingolimod in young patients with Multiple Sclerosis. The study comprises two parts: the Core Part, which spans two years, and the Extension Part, which can last up to five years. In the Core Part, participants are assigned one of the three medications to compare their respective effects. Qualified participants from the Core Part have the option to continue their treatment in the Extension Part. Progress is monitored by assessing the number of disease exacerbations per year, observing changes in scans that detect alterations related to the disease, and conducting blood tests. These blood tests are instrumental in measuring the levels of the medications in the body and ensuring that they do not have adverse effects.

    • Siponimod
    • Ofatumumab
    • Fingolimod
  • Examining how a potential new drug affects Multiple Sclerosis symptoms

    This study is about testing a new medication for people who have a Relapsing Multiple Sclerosis. The main goal of the trial is to find out if IMU-838 is effective and safe. To achieve this, the study will involve a comparison between the outcomes of patients who were administered IMU-838 and those who received a placebo. Neither the patients nor the doctors involved in the study will be aware of whether the participants are taking the actual drug or the placebo. This blinding technique helps to eliminate biases and ensures that the evaluation of outcomes is impartial, enhancing the reliability of the study results.

    • Vidofludimus calcium/IMU-838
  • Comparison of the effectiveness of fingolimod and interferon in multiple sclerosis in children

    This study is about testing a medication called Fingolimod on young patients with Multiple Sclerosis (MS), a condition that affects the nervous system. The main purpose of this study is to check if this medication is safe and effective for these patients. The study will compare Fingolimod with another treatment, Interferon Beta-1a. The entire study will take about 7 years. In the first 2 years, patients will be randomly given either Fingolimod or Interferon Beta-1a without knowing which one they are receiving. In the next 5 years (Extension Phase), all the patients will take Fingolimod. The patients will include children and teenagers. There’s also a smaller group — the younger cohort — these are the kids who are 12 or younger, weigh less than 40 kg, or are not yet in puberty.

    • Interferon beta-1a
    • Fingolimod
  • Understanding ocrelizumab treatment for progressive multiple sclerosis

    This study is exploring how well ocrelizumab works and its safety for people with progressive multiple sclerosis (MS). MS patients will either receive ocrelizumab or a placebo every 24 weeks to see if it helps with their disability, particularly in the upper limbs. The study will also monitor any side effects. It includes several phases, from initial screening to treatment and follow-ups, ending with a B-cell monitoring phase. The study, started in August 2019, is set to complete by November 2030 and includes 1000 participants who are receiving careful medical oversight.

    • Ocrelizumab
  • Effect of ocrelizumab on infants whose mothers have multiple sclerosis or clinically isolated syndrome

    This medical research project is exploring how a certain drug, ocrelizumab, can affect babies whose mothers had taken the drug during pregnancy. The drug is usually used to treat women with certain neurological conditions, such as clinically isolated syndrome (CIS) or multiple sclerosis (MS). This study targets women who had their last dosage of the drug from six months before their last menstrual period up to their first trimester of pregnancy. The study aims to understand how this drug impacts the B cell levels (a type of white blood cell) of the infants born to these mothers.

    • Ocrelizumab